Sling Therapeutics

Today, we announced positive topline efficacy and safety data from the Phase 2b/3 LIDS trial of our oral small molecule, linsitinib, in patients with active, moderate to severe #ThyroidEyeDisease. The LIDS trial met its primary?endpoint of proptosis reduction with statistical significance for the 150mg BID dose. Linsitinib was well-tolerated and consistent with the safety profile of the previous 15 linsitinib clinical trials. The safety profile was favorable particularly in IGF-1R areas of interest such as hearing impairment, glycemic changes, and menstrual cycle changes. No drug related hearing impairment, a 0% placebo adjusted tinnitus rate, and only one case of hyperglycemia that required no medical intervention was reported. Linsitinib is the only oral small molecule therapy to establish statistical and clinical significance in a #TED clinical trial. Read the full release: https://bit.ly/4jcZiwa

We’re excited to announce that Raymond Douglas M.D., Ph.D., Chief Scientific Officer of Sling Therapeutics, will present topline data from the Phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe #ThyroidEyeDisease at the 43rd?Annual J.P. Morgan Healthcare Conference in San Francisco. Join us on Monday, January 13, 2025, at 5:00 p.m. PT for an overview of the company and topline results of the study. Learn more: https://bit.ly/40vdyci #JPM2025 #TED

We are thrilled to announce the appointment of Andrew Guggenhime, a #biopharma executive with nearly three decades of experience, to our Board of Directors. Read the full release: https://bit.ly/3DIAvjv

The Sling team is hanging out at ENDO 2024 now through Tuesday in Boston! Stop by and visit us at Booth 1302!!

Knowing the signs and symptoms of thyroid eye disease (#TED) is key to managing the condition effectively. Learn more via Brigham and Women's Hospital at https://lnkd.in/eeJcKCqa #WomensEyeHealthMonth

This week our team will proudly sponsor and attend the Innovate Thyroid Eye Disease (TED) 2024 Multidisciplinary Symposium in Napa, CA, where we will have the opportunity to connect with fellow experts in #endocrinology and #ophthalmology and discuss the latest research and innovations in #TED. Explore the #InnovateTED agenda here: https://innovateted.com/ Byers Eye Institute at Stanford

Thyroid eye disease (TED) can affect a person’s life in many challenging ways. That’s why we are working to develop a potential new treatment option for #TED. Learn more: https://lnkd.in/exenGqbW

#DYK that two out of every three people living with blindness or vision problems are women? For #healthyvision tips, visit the National Eye Institute (NEI) at https://lnkd.in/dhz-HQ_p #WomensEyeHealthMonth

With over 20 years of experience in #ThyroidEyeDisease (TED), our Chief Scientific Officer, Raymond Douglas M.D., Ph.D., plays a key role in advancing our #TED pipeline and driving high-quality #clinicaldevelopment. Thanks for sharing CheckRare!